Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%–10.5% [53–91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)—all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through a phase 2b trial, cotadutide 300 μg was shown to significantly improve liver injury enzymes, propeptide of type III collagen level, FIB-4, and NAFLD fibrosis score compared to placebo (but not compared to liraglutide) and reduce body weight more than treatment with liraglutide 1.8 mg.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [173]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [239]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“The pathology of NAFLD can progress further to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and end-stage cirrhosis (7).”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundFox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Cited by
Items 201–300 of 324
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
“Administration of cotadutide for 54 weeks to obese patients with T2DM decreased HbA1c levels and body weight and improved the serum lipid pro fi les, liver function, nonalcoholic fatty liver disease fi brosis score, and fi brosis-4 index (Nahra et al., 2021) (Table 1).”
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 8
Designer GLP1 poly-agonist peptides in the management of diabesity
Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 8
“Furthermore, Cotadutide therapy was associated with a significant improvement in the fatty liver index (−8.18 at the 300 µg dose compared with −6.22 and −1.62 in the Liraglutide and placebo groups, respectively).”
BackgroundInfluentialBrodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
“In T2D subjects with overweight/obesity, cotadutide significantly promoted weight loss [29] and its effects on metabolic and hepatic parameters were extensively investigated in a phase 2b study involving 834 patients [30].”
BackgroundWinther‐Sørensen, M., García, S. L., Bartholdy, A., Ottenheijm, M. E., Banasik, K., Brunak, S., Sørensen, C. M., Gluud, L. L., Knop, F. K., Holst, J. J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06160-1 · Cited by 8
“Gluca-gon and GLP-1 impact on glucose control, food intake, and hepatic protein and lipid metabolism [1], and co-agonists of these two hormones are being tested in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [2, 3].”
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Wali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes
Zhao, L., Zou, Y., Wu, Y., Cai, L., Zhao, Y., Wang, Y., Xiao, X., Yang, Q., Yang, J., Ren, H., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1103251 · Cited by 6
“Indeed, the first glucagonlike peptide 1 (GLP-1)/glucagon coagonist (cotadutide) improved glycemic control, weight loss, and even improved metabolic profiles in patients who were overweight or obese and had T2D in a Phase 2b clinical trial (37).”
BackgroundHope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
“9,10 Subsequently, several GCGR-targeted multi-agonists have progressed to early phase clinical trials and have shown promising initial results, including the GLP-1R/ GCGR co-agonists LY3305677, 11 cotadutide 12 and BI 456906.”
BackgroundDuodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects
Zheng, Y., Wang, Y., Xiong, X. B., Zhang, L., Zhu, J., Huang, B., Liu, X., Liu, J., Zhu, Z., Yang, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202400819 · Cited by 11
Salmen, T., Potcovaru, C.-G., Bica, I.-C., Giglio, R. V., Patti, A. M., Stoica, R. A., Ciaccio, M., El‐Tanani, M., Janež, A., Rizzo, M., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101322 · Cited by 8
“…receptor agonists (GLP-1 Ra) [14–20], to dual incretin tirzepatide in SURMOUNT program [21], to the GLP-1 and glucagon receptor agonist cotatutide [22], or even the triple incretin retatrutide [23], and the first results are promising in how clinicians could take action in the obesity pandemic.”
BackgroundInfluentialCamilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
Lindsay, R. T., Ambery, P., Jermutus, L., & Murray, A. J. (2023) · Physiological Reports · doi:10.14814/phy2.15597 · Cited by 5
“Glucagon receptor agonism leads to an improvement in hepatic mitochondrial function, and long- term dual glucagon and GLP- 1 receptor agonism have positive effects on glucose control, weight management, lipid profile, and liver function (Ambery et al., 2018; Boland et al., 2020; Nahra et al., 2021).”
BackgroundSelf-citationBołdys, A., Bułdak, Ł., Skudrzyk, E., Machnik, G., & Okopień, B. (2024) · Endokrynologia Polska · doi:10.5603/ep.99891 · Cited by 6
“Incretin-based therapies were shown to effectively improve markers of steatohepatitis in diabetic, obese subjects [13].”
BackgroundIncretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Liu, Y., Zhao, X., Wang, X., & Zhou, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534628 · Cited by 6
Bertinat, R., Holyoak, T., Gatica, R., Jara, N., González‐Chavarría, I., & Westermeier, F. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102112 · Cited by 5
“Consistent with this, clinical studies suggest that the improvements in hepatic steatosis and fi brosis markers observed with GLP-1/glucagon dual agonists in humans are primarily due to direct hepatic GCGR activation rather than weight loss induced by GLP-1 agonism alone [193,194].”
Alalwani, Y. J., Alshahrani, A. S., Alsudays, A. I., Almutairi, R. A., Arab, R. A. H., Alqahtani, M. S., Alrefaei, O. S., Alqahtani, R. A., Ofaysan, M. S., Azzam, A. Y., et al. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-09022-y · Cited by 10
Targeting the Enteroendocrine System for Treatment of Obesity
Miedzybrodzka, E. L., Gribble, F. M., & Reimann, F. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_583 · Cited by 5
Obesity management for the hepatologist—What to do, how to do it and why?
Watt, K. D. S., Paul, S., Khan, M. Q., Siddiqui, M. S., Lam, J., Diwan, T. S., & Camilleri, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000598 · Cited by 5
Jiang, P., Zeng, Y., Yang, W. Y., Li, L., Zhou, L., Xiao, L., Li, Y., Gu, B., Li, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116485 · Cited by 5
Wang, J.-K., Zhang, D., Wang, J.-F., Lu, W., Wang, J., Liang, S.-F., Liu, R., Jiang, J., Li, H., & Yang, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.99526 · Cited by 6
Patoulias, D., Michailidis, T., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.001 · Cited by 5
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“A similar dual GLP1R/GCGR agonist is MEDI0382, also known as cotadutite, which is under development for T2DM comorbidities, nonalcoholic steatohepatitis (NASH), and chronic kidney disease [56].”
BackgroundFrom genes to care: the expanding therapeutic horizon in rare genetic obesities
Chalopin, S., Guillon, E., Faucher, P., Dubern, B., Clément, K., & Poitou, C. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf007 · Cited by 4
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Madrid, E., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 16
Ji, L., Jiang, H., Cheng, Z., Li, X., Pang, S., Zhang, Y., Qiu, W., MA, Q., Liu, Z., Wang, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101063 · Cited by 4
Prieto, B. L. A., & Lozano, E. W. M. (2001) · Repositorio Institucional Universidad Católica de Colombia (Universidad Católica de Colombia) · Cited by 6
Goodman, J., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
Self-citationKamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Basavarajappa, S. D., Girijashankar, H. B., Joshi, A., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112830 · Cited by 4
“%) had some concerns[10,11,12,16].”
InfluentialFacciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Peptide drugs application in metabolic diseases and discovery strategies
Bin, T. E. N. G., Junfeng, L. I., & Ren, P. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00063-8 · Cited by 7
Carmo‐Silva, S., & Nóbrega, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-62491-9_2 · Cited by 3
Kanbay, M., Çöpür, S., Güldan, M., Özbek, L., Mallamaci, F., & Zoccali, C. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14330 · Cited by 4
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
“…Agonist compared to liraglutide and placebo showed improved lipid profile, AST and ALT levels, pro-peptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score (NFS) were observed with cotadutide 300 mcg versus placebo, but not with liraglutide [71].”
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4755 · Cited by 5
Past and present of beta arrestins: A new perspective on insulin secretion and effect
Güven, B., & Onay-Beşikçi, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175952 · Cited by 5
White Tea Consumption Alleviates Anthropometric and Metabolic Parameters in Obese Patients
Akyıldız, K., Yılmaz, A., Avcı, U., Toraman, M. N., & Yazıcı, Z. A. (2024) · Medicina · doi:10.3390/medicina60101568 · Cited by 5
“In addition, chronic overeating can lead to elevated enzyme levels [35,36].”
BackgroundPancreatic islet remodeling in cotadutide-treated obese mice
Spezani, R., Marinho, T. D. S., Cardoso, L. E. M., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121858 · Cited by 3
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu‐Hilal, L. H., & Leon, B. G. C. (2026) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70187 · Cited by 3
Min, S. H. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.82 · Cited by 2
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01870-x · Cited by 3
“Cotadutide, a GCGR/ GLP-1R agonist, was observed to promote reduction of liver fat and glycogen and improve lipid profile, aspartate [23].”
Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
“In a phase 2b study (NCT03235050), Cotadutide was assessed for HbA1c reduction and improved body weight by week 14 [17].”
InfluentialXiao, Y., Yu, S. P., Zhang, Y., Chen, J., Yan-qun, L., Liu, X., Sun, C., & Deng, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70105 · Cited by 3
The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Tacke, F. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02304-9 · Cited by 3
Incretin therapy and obesity: current and future pharmacologic possibilities
Moss, E., Hawk, K., Lollis, K., & Clements, J. N. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0151 · Cited by 3
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
IMPROVE 2022 International Meeting on Pathway‐Related Obesity : Vision of Excellence
Kühnen, P., Argente, J., Clément, K., Dollfus, H., Dubern, B., Farooqi, I. S., de Groot, C., Grüters, A., Holm, J., Hopkins, M., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12659 · Cited by 2
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 5
Wang, H., & Wu, R. (2025) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2025.2494819 · Cited by 2
“…that metformin treat-ment significantly reduced serum levels of Fatty acid-binding protein 4 (FABP4) and increased levels of Peroxisome proliferator-activated receptor gamma (PPARγ) in patients with Type 2 Diabetes Mellitus (T2DM) complicated by Nonalcoholic Fatty Liver Disease (NAFLD)[16].”
Yu, H., Parker, V., Selvarajah, V., Hansen, L. B., Robertson, D. C., Hamrén, B., Khan, A. A., & PARKINSON, J. R. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70093 · Cited by 2
Lee, C. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.005 · Cited by 3
An emerging direction in glucagon-based therapy
Chen, Y., Yang, D., & Wang, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.004 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Frühbeck, G., & Kiortsis, D. N. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128279822231211101522 · Cited by 2
Les médicaments de l’obésité : état actuel et futures avancées
Lassen, P. B., & Aron‐Wisnewsky, J. (2023) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2023.04.005 · Cited by 3
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
“In a phase 2b study on 834 overweight and obese adults, cotadutide 100, 200 and 300 mcg subcutaneous injections were found to improve transaminase levels and fibrosis scores, though liraglutide was not [45].”
Bosch, R., Petrone, M., Arends, R., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70074 · Cited by 1
“The model was further validated by predicting the effects of co-tadutide and liraglutide on FPG and HbA1c for a typical subject in the cotadutide Ph2b study [11] without considering possible LSCeff.”
Current and Future Implications of Weight Loss Drugs on Liver Disease
Bussetty, A., Shah, N., Chandler, T. M., Ghattu, M., & Kesavarapu, K. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.005 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
“Importantly, post hoc analyses showed favorable changes in hepatic biomarkers and indices of steatosis, supporting its potential role in the treatment of steatohepatitis [75].”
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Obésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
Alshahrani, O. A. S., & Almalki, M. S. (2024) · Cureus · doi:10.7759/cureus.65242 · Cited by 5
“Cotadutide Three RCTs were carried out by Asano et al. (2023) [18], Nahra et al. (2021) [34], and Ambery et al. (2018) [17] to investigate the effects of cotadutide on BW and blood glucose versus placebo.”
BackgroundBariatric and Metabolic Surgery for Diabesity: A Narrative Review
Gangemi, A., & Bernante, P. (2024) · Endocrines · doi:10.3390/endocrines5030029 · Cited by 2
“…a novel role of pharmacotherapy, not as an alternative but as a complementary therapy to BMS. Medications such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and combination therapies are showing potential to maximize weight loss, improve metabolic outcomes, and…”
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 2
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_25 · Cited by 3
Intra-islet glucagon signalling regulates pulsatile insulin secretion and glucose homeostasisPreprint
Suba, K., Patel, Y., Alonso, A. M., Roberts, A. G., Hansen, B., Norton, M., Shrewsbury, J. V., Kwok, R., Kalogianni, V., Chen, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.506223 · Cited by 1
Ali, M., Allam, A. H., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd‐ElGawad, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1236048/v1
Diabetes mellitus 2022 – Was ist neu?
Scherbaum, W. A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00924-2
and, E. J., & Fisher, M. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch14
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Gastrointestinale Hormone – zunehmende arzneitherapeutische Bedeutung bei Stoffwechselerkrankungen
Gallwitz, B. (2023) · Die Innere Medizin · doi:10.1007/s00108-022-01447-0
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_35
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-2
Winther‐Sørensen, M., García, S. L., Bartholdy, A., Ottenheijm, M. E., Banasik, K., Brunak, S., Sørensen, C. M., Gluud, L. L., Knop, F. K., Holst, J. J., et al. (2023) · medRxiv · doi:10.1101/2023.12.12.23299852
Tratamiento farmacológico actual y futuro de la esteatosis hepática
Alonso, N., & Julián, M. T. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.esteatosis.art7
Sanyal, A. J., Muthiah, M. D., & Tan, E. X. X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00029-3
Abdel-Malek, M., Thayabaran, D., & Miras, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00010-3
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_13
Self-citationPharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Pharmacological Interventions of Metabolic Syndrome
Mehta, A. A., Beladiya, J., & Gandhi, T. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_22 · Cited by 2
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Li, J., Ni, W., Bai, X., Zhou, S., Wu, X., Li, J., Jiang, Z., Wu, J., Li, M., Wong, H.-N., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5083838
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
“…↓ HbA 1c and body weight vs PL after 14 wks, which was sustained to 54 wks; however, these improvements were not superior to liraglutide treatment [41] Common AEs were nausea and vomiting; both eased over time [41] Mazdutide (LY3305677 or IBI362) An interim analysis from a phase 2 RCT…”
Pagès, L., Martí‐Carretero, A., Rojo, D., Sabiote, C., Faninam, F., Parks, S. C., Martínez-Gómez, M., Cusidó, M. S., Akhlaghi, N., Muñoz, S., et al. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00692-9 · Cited by 1
“Moreover, treatment with cotadutide 300µg was the only intervention that showed a significant reduction in the fibrogenic biomarker pro-C3 compared to placebo [39].”
InfluentialTraitement pharmacologique des obésités complexes d’origine génétique
Faccioli, N., Dubern, B., Clément, K., & Poitou, C. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48025-6
Du, Y., Liu, T., Li, H.-L., Luo, Q., Guo, X.-Y., Wang, J., Wang, X., Zhou, Y.-M., Pan, Y., Yu, L., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00261
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Exploring the therapeutic landscape of glucagon
Paila, D., Bansal, P., Aggarwal, R., & Prakash, A. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_23_25
Metadata
- Authors
- Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P.
- Affiliations
- AstraZeneca (United States) (US)
- Pennington Biomedical Research Center (US)
- AstraZeneca (Sweden) (SE)
- 5Division of Endocrinology, University Hospital Leipzig, Leipzig, Germany
- AstraZeneca (United Kingdom) (GB)
- 4Clinical Metabolism, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Corresponding author
- Nahra, Rajaa
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8247525
- OpenAlex
- W3160773731
- Semantic Scholar
- 0019fb9a1c6044e014f9a7ae0dd18ea9907668eb
- Cited by
- 323
- References
- 47
- Citations by year
- 2026: 36 · 2025: 65 · 2024: 76 · 2023: 83 · 2022: 48 · 2021: 14
- FWCI
- 41.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, glucagon receptor agonist, type 2 diabetes, obesity, overweight, glycemic control, HbA1c, weight loss, non-alcoholic fatty liver disease, liver fibrosis, liver injury biomarkers, liraglutide, lipid profile, adverse events, nausea and vomiting, dose comparison
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Obesity, Peptides, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.